Allogeneic cell therapies are advancing in clinical trials, requiring oncologists and pathologists to understand the ...

I’ve endured numerous rounds of radiation and taken thousands of pills—but CAR-T is the most effective therapy I’ve completed ...

Ichnos Glenmark Innovation subsidiary IGI Therapeutics has signed an exclusive licensing agreement with AbbVie for ISB 2001, ...

Market Trends, Business Strategies, Competitive Intelligence, Clinical Trials, and Patent Trends Driving Growth from 2024 to 2029"Boston, July 10, 2025 (GLOBE NEWSWIRE) -- According to the latest ...

ALLO-316 shows promising results in advanced renal cell carcinoma, with a 25% response rate and rapid treatment turnaround, ...

Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases. Promising results, but Phase ...

In recent years, the FDA has approved three complement inhibitors for gMG -- eculizumab (Soliris), ravulizumab (Ultomiris), ...

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...

A team of physicians recently reported the successful treatment of refractory autoimmune neuropathies through the infusion of ...

Several ASX-listed biotechs are advancing cell therapies to capture a share of a global market projected to reach US$48 ...

Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, discussed the complexities of alternative payment models for ...

Despite promising science, Precigen has long-faced severe financial challenges and a very short cash runway into 2026. Click ...